Volume 73, Issue 5 p. 475-477
Letters to the Editor

Cytochrome P4502C9 activity in end-stage renal disease

Albert W. Dreisbach MD

Albert W. Dreisbach MD

Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA

Search for more papers by this author
Shanker Japa PhD

Shanker Japa PhD

Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA

Search for more papers by this author
Aster B. Gebrekal BS

Aster B. Gebrekal BS

Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA

Search for more papers by this author
Sarah E. Mowry BS

Sarah E. Mowry BS

Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA

Search for more papers by this author
Juan J. L. Lertora MD, PhD

Juan J. L. Lertora MD, PhD

Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA

Search for more papers by this author
Burde L. Kamath PhD

Burde L. Kamath PhD

Department of Pharmacokinetics, Xavier University College of Pharmacy, New Orleans, La, USA

Search for more papers by this author
Allan E. Rettie PhD

Allan E. Rettie PhD

Department of Medicinal Chemistry, University of Washington School of Pharmacy, Seattle, Wash, USA

Search for more papers by this author
First published: 17 May 2003
Citations: 84
No abstract is available for this article.